CPRX News and Press, Catalyst Pharmaceuticals Inc. From 08/08/19

Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2019 Earnings Conference Call August 8, 2019 8:30 A.M. ET Company Participants Alicia Grande - Chief Financial Officer Pat McEnany - Chairman and Chief Executive Officer Dan Brennan - Chief Commercial Officer Steve Miller - Chief Operati...

Catalyst Pharmaceuticals (NASDAQ: CPRX ): Q2 GAAP EPS of $0.10 beats by $0.07 . More news on: Catalyst Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...

Firdapse ® Launch Momentum Continues with Second Quarter Net Revenues of $28.8 Million 409 Adult LEMS Patients Active on Firdapse as of June 30, 2019 Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla., Aug. 07, 2019 (GLOBE NEWSWIRE)...

AAOI , AGO , AIG , ALB , AMPH , ANGI , ARNA , ASRT , ATO , AVLR , AZPN , BKNG , BREW , CABO , CAI , CCMP , CDE , CECO , CLI , COLL , CPA , CPRX , CSGS , CTL , CVNA , CWH , DAR , DOX , DVAX , EB , ECPG , ENS , ENV , ET , EVRG , FG , FLO , FNV , FOSL , ...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 114 weeks of public selections as part of this ongoing live forward-testing. In...

CORAL GABLES, Fla., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...

CORAL GABLES, Fla., July 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 114 weeks of public selections as part of this ongoing live forward-testing. In...

Shares of Catalyst Pharmaceuticals ( CPRX ) have risen by 30% since my May article noted that the panic selling on FDA approval of Jacobus Pharma's Ruzurgi appeared overdone. I certainly failed to nail the bottom, but despite this surprising move by the regulatory agency, much of the long th...

Editor's note: Seeking Alpha is proud to welcome Illuminate Capital as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Editor's not...